Locquet, M., Beaudart, C., Pétermans, J., Reginster, J., & Bruyère, O. (2019). EWGSOP2 Versus EWGSOP1: Impact on the Prevalence of Sarcopenia and Its Major Health Consequences.
Cita Chicago (17th ed.)Locquet, Médéa, Charlotte Beaudart, Jean Pétermans, Jean‐Yves Reginster, i Olivier Bruyère. EWGSOP2 Versus EWGSOP1: Impact on the Prevalence of Sarcopenia and Its Major Health Consequences. 2019.
Cita MLA (9th ed.)Locquet, Médéa, et al. EWGSOP2 Versus EWGSOP1: Impact on the Prevalence of Sarcopenia and Its Major Health Consequences. 2019.
Atenció: Aquestes cites poden no estar 100% correctes.